Search Results - "Horjus Talabur Horje, C. S."

Contrast Enhanced Abdominal Ultrasound in the Assessment of Ileal Inflammation in Crohn's Disease: A Comparison with MR Enterography by Horjus Talabur Horje, C S, Bruijnen, R, Roovers, L, Groenen, M J M, Joosten, F B M, Wahab, P J

“…To prospectively examine the feasibility and accuracy of Contrast Enhanced Ultrasound (CEUS) in the assessment of Crohn's disease (CD) activity in the terminal…”
Get full text

High endothelial venules associated with T cell subsets in the inflamed gut of newly diagnosed inflammatory bowel disease patients by Horjus Talabur Horje, C. S., Smids, C., Meijer, J. W. R., Groenen, M. J., Rijnders, M. K., van Lochem, E. G., Wahab, P. J.

“…Summary Naive and central memory T lymphocytes (TN and TCM) can infiltrate the inflamed gut mucosa in inflammatory bowel disease (IBD) patients. Homing of…”
Get full text

P019 Colonic mucosal kinase activity, cytokine and chemokine profiles in inflammatory bowel disease by Brand, E, Roosenboom, B, Malvar Fernandez, B, Lutter, L, van Koolwijk, E, van Lochem, E G, Horjus Talabur Horje, C S, Reedquist, K A, van Wijk, F, Oldenburg, B

“…Abstract Background With the approval of tofacitinib, an oral Janus Kinase (JAK) inhibitor, modulation of kinase activity has been added to the therapeutic…”
Get full text

DOP58 Tofacitinib for ulcerative colitis: Results of the ICC Registry, a nationwide prospective observational cohort study by Biemans, V B, Sleutjes, J A M, de Vries, A C, Bodelier, A G, Dijkstra, G, Oldenburg, B, Löwenberg, M, van Bodegraven, A A, van der Meulen-de Jong, A E, de Boer, N K, Srivastava, N, West, R L, Römkens, T, Horjus Talabur Horje, C S, Jansen, J M, Hoekstra, J, Weersma, R K, van Schaik, F D, Hoentjen, F, Pierik, M J

“…Abstract Background Tofacitinib is a janus kinase 1 and 3 inhibitor approved for the treatment of ulcerative colitis (UC). Real-world evidence is needed to…”
Get full text